Targeting antibiotic resistant bacteria with phage reduces bacterial density in an insect host.
Enterobacter cloacae
antibiotic resistance
bacteriophage
gut infection
insect model
phage therapy
Journal
Biology letters
ISSN: 1744-957X
Titre abrégé: Biol Lett
Pays: England
ID NLM: 101247722
Informations de publication
Date de publication:
29 03 2019
29 03 2019
Historique:
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
18
12
2019
Statut:
ppublish
Résumé
Phage therapy is attracting growing interest among clinicians as antibiotic resistance continues becoming harder to control. However, clinical trials and animal model studies on bacteriophage treatment are still scarce and results on the efficacy vary. Recent research suggests that using traditional antimicrobials in concert with phage could have desirable synergistic effects that hinder the evolution of resistance. Here, we present a novel insect gut model to study phage-antibiotic interaction in a system where antibiotic resistance initially exists in very low frequency and phage specifically targets the resistance bearing cells. We demonstrate that while phage therapy could not reduce the frequency of target bacteria in the population during positive selection by antibiotics, it alleviated the antibiotic induced blooming by lowering the overall load of resistant cells. The highly structured gut environment had pharmacokinetic effects on both phage and antibiotic dynamics compared with in vitro: antibiotics did not reduce the overall amount of bacteria, demonstrating a simple turnover of gut microbiota from non-resistant to resistant population with little cost. The results imply moderate potential for using phage as an aid to target antibiotic resistant gut infections, and question the usefulness of in vitro inferences.
Identifiants
pubmed: 30836884
doi: 10.1098/rsbl.2018.0895
pmc: PMC6451383
doi:
Substances chimiques
Anti-Bacterial Agents
0
Banques de données
Dryad
['10.5061/dryad.sc54383']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20180895Subventions
Organisme : Medical Research Council
ID : MR/N013824/1
Pays : United Kingdom
Références
Trends Microbiol. 2009 Feb;17(2):66-72
pubmed: 19162482
Lancet. 2001 Jul 14;358(9276):135-8
pubmed: 11463434
J Virol. 1974 Sep;14(3):689-99
pubmed: 4211861
Biol Lett. 2011 Dec 23;7(6):902-5
pubmed: 21632619
Nature. 2014 Jun 5;510(7503):15-6
pubmed: 24899282
BMC Genomics. 2009 Feb 09;10:71
pubmed: 19203375
Proc Natl Acad Sci U S A. 2017 Sep 5;114(36):9641-9646
pubmed: 28830993
Genetics. 2003 Dec;165(4):1641-9
pubmed: 14704155
mSystems. 2018 Oct 2;3(5):
pubmed: 30320219
Cell Host Microbe. 2017 Jul 12;22(1):38-47.e4
pubmed: 28704651
J Antibiot (Tokyo). 2014 Sep;67(9):625-30
pubmed: 25118103
EBioMedicine. 2016 Jan 05;4:124-37
pubmed: 26981577
Antimicrob Agents Chemother. 2018 May 25;62(6):
pubmed: 29555626
Biotechnol J. 2016 May;11(5):595-600
pubmed: 27008250
Evol Med Public Health. 2018 Mar 08;2018(1):60-66
pubmed: 29588855
Trends Microbiol. 2015 Mar;23(3):126-33
pubmed: 25680587
Appl Environ Microbiol. 2014 Jul;80(14):4374-82
pubmed: 24814787
Evol Appl. 2013 Sep;6(6):925-32
pubmed: 24062801
Antimicrob Agents Chemother. 2009 May;53(5):2205-8
pubmed: 19223640
J Bacteriol. 1971 Dec;108(3):1244-9
pubmed: 4945193
Trends Microbiol. 2016 Apr;24(4):249-256
pubmed: 26786863
Clin Pharmacol Ther. 2000 Sep;68(3):225-30
pubmed: 11014403
J Appl Microbiol. 2000 Jan;88(1):90-7
pubmed: 10735247
Expert Rev Gastroenterol Hepatol. 2017 Sep;11(9):785-788
pubmed: 28612636
FEMS Microbiol Lett. 2004 Mar 12;232(1):1-6
pubmed: 15061140
Clin Otolaryngol. 2009 Aug;34(4):349-57
pubmed: 19673983
Biol Lett. 2019 Mar 29;15(3):20180895
pubmed: 30836884